Incannex Healthcare Limited

NasdaqGM IXHL

Incannex Healthcare Limited Interest Coverage Ratio for the year ending June 30, 2024

Incannex Healthcare Limited Interest Coverage Ratio is NA for the year ending June 30, 2024. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.
  • Incannex Healthcare Limited Interest Coverage Ratio for the year ending June 30, 2023 was -4,526.39, a 87.40% change year over year.
  • Incannex Healthcare Limited Interest Coverage Ratio for the year ending June 30, 2022 was -35,936.83, a -104.92% change year over year.
  • Incannex Healthcare Limited Interest Coverage Ratio for the year ending June 30, 2021 was 730,006.81, a 2,407.53% change year over year.
  • Incannex Healthcare Limited Interest Coverage Ratio for the year ending June 30, 2020 was 29,112.60, a 198,776.93% change year over year.
Key data
Date Interest Coverage Ratio Debt to Equity Ratio Interest Expense To Sales Inventory Turnover Ratio
Market news
Loading...
NasdaqGM: IXHL

Incannex Healthcare Limited

CEO Mr. Joel Bradley Latham
IPO Date March 2, 2022
Location Australia
Headquarters 207/11 Solent Circuit
Employees 9
Sector Health Care
Industries
Description

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.

Similar companies

RGC

Regencell Bioscience Holdings Limited

USD 4.86

-4.71%

PBH

Prestige Consumer Healthcare Inc.

USD 75.78

1.54%

PAHC

Phibro Animal Health Corporation

USD 20.28

0.05%

ANIP

ANI Pharmaceuticals, Inc.

USD 54.16

0.43%

COLL

Collegium Pharmaceutical, Inc.

USD 33.18

-1.80%

PROC

Procaps Group S.A.

USD 1.76

7.98%

StockViz Staff

January 15, 2025

Any question? Send us an email